The SLC22A3 antibody targets the solute carrier family 22 member 3 (SLC22A3), a polyspecific organic cation transporter encoded by the SLC22A3 gene located on human chromosome 6q25.3. SLC22A3. also known as OCT3. facilitates the transport of organic cations, including endogenous compounds (e.g., dopamine, epinephrine) and exogenous drugs (e.g., metformin, cisplatin), across cell membranes. It is expressed in various tissues, such as the liver, kidney, placenta, and blood-brain barrier, playing critical roles in drug disposition, toxin clearance, and neurotransmitter regulation.
Research on SLC22A3 has linked it to diseases like cancer, diabetes, and cardiovascular disorders, where its dysregulation may influence drug response or disease progression. For example, SLC22A3 polymorphisms are associated with altered pharmacokinetics of anticancer drugs, while its overexpression in tumors may affect chemoresistance. The SLC22A3 antibody is widely used in biomedical research to detect protein expression levels, cellular localization, and functional studies via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validating antibody specificity is crucial due to potential cross-reactivity with homologous transporters (e.g., OCT1/OCT2). Understanding SLC22A3's role through antibody-based assays aids in elucidating its physiological and pathological mechanisms, offering insights into therapeutic targeting and personalized medicine strategies.